Gareth Edward King
Direktor/Vorstandsmitglied bei Proveca Ltd.
Profil
Dr. Gareth E.
King is Life Science Partner at Catapult Venture Managers Ltd.
Prior to joining Catapult Venture, Dr. King was Chief Executive Officer at Critical Pharmaceuticals Ltd, Project Leader at AstraZeneca Pharmaceuticals LP, Researcher at Harvard Medical School, a Principal at Cyprotex Plc and Incyte Pharmaceuticals, Inc.
Dr. King received his BSc in Microbiology from The University of Sheffield and a PhD in Molecular Genetics from The University of Edinburgh.
Aktive Positionen von Gareth Edward King
Unternehmen | Position | Beginn |
---|---|---|
Catapult Ultimate Holdings Ltd.
Catapult Ultimate Holdings Ltd. Investment ManagersFinance Catapult Ultimate Holdings Ltd (Catapult Ultimate Holdings) is an independent venture capital firm founded in 1999. The firm is headquartered in Leicester, United Kingdom. | Private Equity Investor | - |
Proveca Ltd.
Proveca Ltd. Pharmaceuticals: MajorHealth Technology Proveca Ltd. develops pharmaceuticals for children and adults through studies dedicated to providing evidence for the specific use of off-patent medicines. The firm develops medicines for children in the fields of cardiology, neurology, and pain management. The company was founded by Simon Peter Bryson and Helen Margaret Shaw in July 2010 and is headquartered in Warrington, the United Kingdom. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Gareth Edward King
Unternehmen | Position | Ende |
---|---|---|
CYPROTEX PLC | Corporate Officer/Principal | - |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company was founded in April, 1991 is headquartered in Palo Alto, CA. | Corporate Officer/Principal | - |
Harvard Medical School | Corporate Officer/Principal | - |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Corporate Officer/Principal | - |
Critical Pharmaceuticals Ltd.
Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Critical Pharmaceuticals Ltd. operates as a clinical stage biotechnology company with interest in developing and producing biological drug products. The company product pipeline includes CP024: Nasal hGH, CP046: Nasal PTH, CP016: hGH Depot and CP018: Risperidone. Critical Pharmaceuticals was founded by Steve Howdle and Kevin Morris Shakesheff in 2002 and is headquartered in Nottingham, the United Kingdom. | Vorstandsvorsitzender | - |
Ausbildung von Gareth Edward King
The University of Sheffield | Undergraduate Degree |
The University of Edinburgh | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 6 |
---|---|
Critical Pharmaceuticals Ltd.
Critical Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Critical Pharmaceuticals Ltd. operates as a clinical stage biotechnology company with interest in developing and producing biological drug products. The company product pipeline includes CP024: Nasal hGH, CP046: Nasal PTH, CP016: hGH Depot and CP018: Risperidone. Critical Pharmaceuticals was founded by Steve Howdle and Kevin Morris Shakesheff in 2002 and is headquartered in Nottingham, the United Kingdom. | Health Technology |
AstraZeneca Pharmaceuticals LP
AstraZeneca Pharmaceuticals LP Pharmaceuticals: MajorHealth Technology AstraZeneca Pharmaceuticals LP develops, manufactures and markets prescription pharmaceutical drugs. It sells products related to gastrointestinal, cardiovascular, neuroscience, respiratory and oncology infections. The company was founded in 1953 and is headquartered in Wilmington, DE. | Health Technology |
Incyte Pharmaceuticals, Inc.
Incyte Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Incyte Pharmaceuticals, Inc. engages in the provision of biopharmaceutical services. The company was founded in April, 1991 is headquartered in Palo Alto, CA. | Health Technology |
Cyprotex Ltd.
Cyprotex Ltd. Miscellaneous Commercial ServicesCommercial Services Cyprotex Ltd. provides pharmaceutical research and development services. It offers ADME and pharmacokinetic, Biosciences, in vitro skin and ocular testing, physicochemical profiling, in vitro toxicology, in silico prediction, and endocrine disruption. The company was founded by David Leahy in 1999 and is headquartered in Abingdon, the United Kingdom. | Commercial Services |
Catapult Ultimate Holdings Ltd.
Catapult Ultimate Holdings Ltd. Investment ManagersFinance Catapult Ultimate Holdings Ltd (Catapult Ultimate Holdings) is an independent venture capital firm founded in 1999. The firm is headquartered in Leicester, United Kingdom. | Finance |
Proveca Ltd.
Proveca Ltd. Pharmaceuticals: MajorHealth Technology Proveca Ltd. develops pharmaceuticals for children and adults through studies dedicated to providing evidence for the specific use of off-patent medicines. The firm develops medicines for children in the fields of cardiology, neurology, and pain management. The company was founded by Simon Peter Bryson and Helen Margaret Shaw in July 2010 and is headquartered in Warrington, the United Kingdom. | Health Technology |